Longeveron receives US patent for stem cell therapy treating frailty

Longeveron Inc. (NASDAQ: LGVN) received a US patent for methods of treating aging-related frailty using mesenchymal stem cells, according to a company statement.

The United States Patent and Trademark Office granted Patent No. 12,465,620, titled "Method of Treating Aging Frailty in Subjects with Inflammaging Using Human Mesenchymal Stem Cells." The patent provides rights through 2038, with potential extensions available.

The patent covers administration of isolated allogeneic mesenchymal stem cells to patients with aging-related frailty characterized by inflammaging. The condition affects older individuals and includes symptoms of weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss.

Longeveron stated no approved treatments currently exist for aging-related frailty, which the company describes as a syndrome that impairs healthspan in older adults. The condition shows correlation with inflammation, according to the company.

The company has conducted Phase 1 and Phase 2 clinical trials for its mesenchymal stem cell therapy laromestrocel in aging-related frailty. The trials measured improvements in six-minute walk tests and physical functioning.

Laromestrocel consists of cells isolated from bone marrow of young healthy adult donors. The therapy targets multiple mechanisms including anti-inflammatory and tissue repair functions.

Longeveron currently develops treatments for hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy. The company's programs have received five FDA designations including Orphan Drug, Fast Track, and Rare Pediatric Disease designations.

You May Also Be Interested In